Please login to the form below

Not currently logged in
Email:
Password:

Emend

This page shows the latest Emend news and features for those working in and with pharma, biotech and healthcare.

CHMP October meeting gives recommendations for Pfizer and MSD

CHMP October meeting gives recommendations for Pfizer and MSD

Merck Sharpe &Dohme's Emend (aprepitant) was further recommended for the prevention of nausea and vomiting in child chemotherapy patients from the age of 6 months to 12 years.

Latest news

  • Merck plans expanded filing for Emend this year Merck plans expanded filing for Emend this year

    Merck &Co's nausea and vomiting therapy Emend is effective in preventing chemotherapy-induced nausea and vomiting (CINV) even when given as a single dose, says a new study. ... Emend has been a solid product for Merck &Co, with sales last year rising 9%

  • Breathing easier

    Allergic rhinitis . Japan. Aprepitant . Emend (Ono Pharmaceutical). Chemotherapy-induced nausea and vomiting  .

  • Breathing life Breathing life

    Aprepitant. Emend (Ono Pharmaceutical). Chemotherapy induced nausea and vomiting. Japan. Sitagliptin.

  • Cost of living

    For example, anti-nausea drugs in the NK-1 class such as Emend make chemotherapy more manageable for high-need patients, thereby improving the likelihood of success for the primary therapy.

  • Elan and J&JPRD submit NDA for novel Invega reformulation

    Rapamune (sirolimus), which is marketed by Wyeth: and the anti-emetic treatment Emend (aprepitant), which is marketed by Merck &Co.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics